Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.56 |
| ▸ | RELA | Q04206 | 1/20 | 0.56 |
| ▸ | NR1H2 | P55055 | 10/20 | 0.54 |
| ▸ | NR1H3 | Q13133 | 10/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.54 |
| ▸ | POLB | P06746 | 4/20 | 0.45 |
| ▸ | RYR1 | P21817 | 2/20 | 0.34 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29374025 | 0.80 | NFKB1 (0.69) | NFKB1NFKB2RELANR1H2NR1H3 | |
| SCHEMBL29623815 | 0.80 | NR1H2 (0.78) | NFKB1NFKB2RELANR1H2NR1H3 | |
| Acerogenin B SCHEMBL13698043 | 0.77 | NFKB1 (0.52) | NFKB1NFKB2RELANR1H2NR1H3 | |
| Acerogenin A SCHEMBL10048511 | 0.77 | NFKB1 (0.52) | NFKB1NFKB2RELANR1H2NR1H3 | |
| Acerogenin B SCHEMBL329405 | 0.77 | NFKB1 (0.52) | NFKB1NFKB2RELANR1H2NR1H3 | |
| Acerogenin E SCHEMBL23268432 | 0.76 | NFKB1 (0.45) | NFKB1NFKB2RELANR1H2NR1H3 | |
| Acerogenin E SCHEMBL29889247 | 0.76 | NFKB1 (0.45) | NFKB1NFKB2RELANR1H2NR1H3 | |
| SCHEMBL10048502 | 0.71 | NR1H2 (0.44) | NFKB1NFKB2RELANR1H2NR1H3 | |
| Riccardi C SCHEMBL29606810 | 0.70 | NR1H2 (1.00) | NFKB1NFKB2RELANR1H2NR1H3 | |
| Riccardin D SCHEMBL30335734 | 0.69 | NR1H2 (0.73) | NR1H2NR1H3PTGS1PTGS2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2407160-B1 | Pharmaceutical composition for prevention and/or treatment of bone disease, functional food or health food comprising the composition, and pharmaceutical preparation comprising the composition as active ingredient | AKIHISA TOSHIHIRO (JP) | 2016-07-27 | — | — | EP | disclosed |
| US-8822705-B2 | Pharmaceutical composition for preventing and/or treating bone disease, functional food or health food and pharmaceutical preparation comprising thereof as active ingredient | Akihisa, Toshihiro (JP) | 2014-09-02 | — | — | US | disclosed |
| US-20090227527-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING BONE DISEASE, FUNCTIONAL FOOD OR HEALTH FOOD AND PHARMACEUTICAL PREPARATION COMPRISING THEREOF AS ACTIVE INGREDIENT | Akihisa, Toshihiro (JP) | 2009-09-10 | — | — | US | disclosed |
| EP-2050442-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND/OR TREATMENT OF BONE DISEASE, FUNCTIONAL FOOD OR HEALTH FOOD COMPRISING THE COMPOSITION, AND PHARMACEUTICAL PREPARATION COMPRISING THE COMPOSITION AS ACTIVE INGREDIENT | Akihisa, Toshihiro (JP) | 2009-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227527-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING BONE DISEASE, FUNCTIONAL FOOD OR HEALTH FOOD AND PHARMACEUTICAL PREPARATION COMPRISING THEREOF AS ACTIVE INGREDIENT | HRH1, HRH2, HRH3 | NFKB1 388/4885NFKB2 1238/4885RELA 364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.